ReviewInternational journal of urology : official journal of the Japanese Urological Association2008
Alpha1-adrenoceptor subtypes and lower urinary tract symptoms.
Review in International journal of urology : official journal of the Japanese Urological Association, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 5 syntheses or guidelines pooled it, 184 citations in OpenAlex.
- Molecular Mechanism Operating in Animal Models of Neurogenic Detrusor Overactivity: A Systematic Review Focusing on Bladder Dysfunction of Neurogenic Origin.International journal of molecular sciences · 2023Pooled it
- Pooled it
- Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2018Pooled it
- Silodosin is effective for treatment of LUTS in men with BPH: a systematic review.Asian journal of andrology · 2013Pooled it
- The efficacy and safety of silodosin in treating BPH: a systematic review and meta-analysis.International urology and nephrology · 2012Pooled it
- Beneficial effects of saw palmetto (Nutrition and health · 2025Trial
- An open-label, prospective interventional study of the tolerability and efficacy of 0.4 mg oral tamsulosin oral controlled absorption system in men with lower urinary tract symptoms associated with benign prostatic hyperplasia who are unsatisfied with treatment with 0.2 mg tamsulosin.Clinical interventions in aging · 2018Trial
- A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia.Medical science monitor : international medical journal of experimental and clinical research · 2016Trial
- The impact of adding low-dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia.World journal of urology · 2015Trial
- Ramelteon combined with an α1-blocker decreases nocturia in men with benign prostatic hyperplasia.BMC urology · 2013Trial
- Tamsulosin shows a higher unbound drug fraction in human prostate than in plasma: a basis for uroselectivity?British journal of clinical pharmacology · 2011Trial
- Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH.Prostate cancer and prostatic diseases · 2011Trial
- Green chemistry for prostate health: exploring nature's toolbox against cancer, inflammation, and hyperplasia.Molecular diversity · 2026Review
- Cardiovascular effects of doxazosin in the treatment of prostatic hyperplasia.Drugs in context · 2026Article
- Review
- Prostogrit mitigates testosterone/estradiol induced prostatic enlargement/remodeling in rat model of benign prostatic hyperplasia and fine-tunes prostatic expression ofFrontiers in endocrinology · 2025Article
- Adreno-Muscarinic Synergy of Contractile Responses From Human Hyperplastic Prostate.International neurourology journal · 2024Article
- Adrenoceptors in the Lower Urinary Tract.Handbook of experimental pharmacology · 2024Review
- Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia.JAMA network open · 2023Article
- Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalafil and Finasteride.Journal of personalized medicine · 2023Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Benign prostatic hyperplasia (BPH) is a common cause of urinary outflow obstruction in aging men leading to lower urinary tract symptoms (LUTS). alpha(1)-Adrenoceptors (alpha(1)ARs) antagonists (blockers) have become a mainstay of LUTS treatment because they relax prostate smooth muscle and decrease urethral resistance, as well as relieving bladder LUTS symptoms. A review of key recent clinical trials suggests new insights into the role of specific alpha(1)AR subtypes in the treatment of LUTS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.